Clinical trials: Tuberculosis (TB)
Tuberculosis
Safety and Immunogenicity of MVA85A, in Healthy Volunteers in Cape Town
This study is designed to evaluate the safety of MVA85A in healthy volunteers in Cape Town. We have shown that MVA85A is safe and immunogenic in both a mycobacterially naïve population in the UK and in a more mycobacterially…
- Trial name
- NCT00460590
- Testing
- MVA 85A
- Where
- South Africa
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Substance-Related Disorders, Mental Disorder
Community Health Worker Training to Reduce Depression and Substance Use Stigma in TB/HIV Care in South Africa
Poor engagement in care contributes to HIV- and TB-related morbidity and mortality in South Africa (SA). Community health workers (CHWs) are frontline lay health workers who work to re-engage patients who are lost to follow-up…
- Conditions
- Substance-Related Disorders, Mental Disorder, Social Stigma, Depression
- Trial name
- Siyakhana (NCT05282173)
- Testing
- Siyakhana CHW Training
- Where
- South Africa
- Volunteers
- 82 people, healthy volunteers welcome
- Sponsor
- University of Maryland, College Park
Tuberculosis, HIV
PREVAIL VIIIa: Evaluation of Latent Tuberculosis Infection Screening Methods in People Living With Retroviral Infection in Liberia
Background: Tuberculosis (TB) is a health threat for people living with human immunodeficiency virus (HIV). People living with HIV are more likely than others to develop active TB. Also, TB makes HIV progress faster.
- Trial name
- NCT04926922
- Where
- 5 sites in United States, Liberia
- Volunteers
- 200 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Latent Tuberculosis Infection
TB mHealth Study - Use of Cell Phones to Improve Compliance in Patients on LTBI Treatment
This study will examine the impact of use of mobile phones and text messaging on adherence to treatment for patients with latent TB infection.
- Trial name
- NCT01549457
- Testing
- Cell phone text messages
- Where
- 3 sites in Canada
- Volunteers
- 350 people
- Sponsor
- University of British Columbia
Tuberculosis
Tuberculosis (TB) Immunotherapy Phase 2 Study
This is a phase II, randomized, placebo-controlled trial, aimed to seek the therapeutic benefit of V7 in combination with standard of care anti-Tuberculosis (TB) therapy (ATT) among Mycobacterium tuberculosis-infected sputum…
- Trial name
- imm02 (NCT01380119)
- Testing
- V7
- Where
- Ukraine
- Volunteers
- 40 people
- Sponsor
- Lisichansk Regional Tuberculosis Dispensary
Human Immunodeficiency Virus, Mycobacterium Tuberculosis
Characteristics and Outcomes of TB and HIV Co-infections
People Living with HIV (PLHIV) are prone to several opportunistic infections depending on the degree of immunosuppression as well as infections prevalent in their geographic area/country.
- Trial name
- NCT06531772
- Testing
- Antitubercular Agents
- Where
- Egypt
- Volunteers
- 100 people
- Sponsor
- Assiut University
Tuberculosis (TB), Uveitis
Six-months Versus Nine-months ATT for Ocular TB
The goal of this clinical trial is to learn if 6-months anti-TB therapy is not worse than 9-months therapy for the treatment of tubercular posterior uveitis.
- Conditions
- Tuberculosis (TB), Uveitis, Retinal Vasculitis, Choroiditis
- Trial name
- NCT06613919
- Testing
- Anti-Tuberculosis Treatment
- Where
- 3 sites in Burma, India and 1 more
- Volunteers
- 58 people
- Sponsor
- L.V. Prasad Eye Institute
Tuberculosis
A Trial of the C-Tb Skin Test, When Given Intradermally to Healthy Volunteers Previously Vaccinated With BCG
A new, more specific skin test to detect tuberculosis has been developed by Statens Serum Institut in Denmark. The new skin test is named C-Tb and like the current Tuberculin a positive test result will show as redness and/or…
- Trial name
- TESEC-03 (NCT01242475)
- Testing
- C-Tb, 2 TU Tuberculin PPD RT 23 SSI
- Where
- United Kingdom
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- Statens Serum Institut
Tuberculosis, Multidrug-Resistant, Infection, Bacterial
Evaluating Newly Approved Drugs for Multidrug-resistant TB
endTB Clinical Trial a Phase III, randomized, controlled, open-label, non-inferiority, multi-country trial evaluating the efficacy and safety of five new, all-oral, shortened regimens for multidrug-resistant tuberculosis (MDR-TB).
- Conditions
- Tuberculosis, Multidrug-Resistant, Infection, Bacterial, Pulmonary Tuberculoses
- Trial name
- endTB (NCT02754765)
- Testing
- Bedaquiline, Delamanid, Clofazimine
- Where
- 12 sites in Georgia, India and 5 more
- Volunteers
- 754 people
- Sponsor
- Médecins Sans Frontières, France
Hiv, Tuberculosis
Interrupting HIV and TB Stigma in the Household in Uganda
The investigators will carry out a prospective, household cluster-randomized, implementation trial evaluating a complex, multi-component, social and behavioral intervention designed to normalize the acceptance of HIV testing in…
- Conditions
- Hiv, Tuberculosis, Social Behavior, Stigma, Social
- Trial name
- NCT05124665
- Testing
- Social Support
- Where
- Uganda
- Volunteers
- 612 people, healthy volunteers welcome
- Sponsor
- Yale University
Drug-Induced Acute Liver Injury, Tuberculosis (TB)
Silymarin Versus N-Acetylcysteine as Protective Effect Against Anti-tuberculosis Drugs Induced Liver Injury.
Worldwide, tuberculosis (TB) infection caused by Mycobacterium Tuberculosis, remains one of the top 10 deadly diseases having a significant socioeconomic burden in the world, especially in developing countries.
- Trial name
- NCT07875322
- Testing
- Antituberculosis drugs Group
- Where
- Egypt
- Volunteers
- 102 people
- Sponsor
- Assiut University
Tuberculosis
A Trial of Stratified Patient-Centered Treatment Regimens for Active TB (SPECTRA-TB)
The A5414 study will evaluate whether treatment for drug-susceptible pulmonary tuberculosis (TB) can be tailored according to a participant's risk of an unfavorable outcome.
- Trial name
- NCT07595042
- Testing
- Isoniazid, Rifampin, Pyrazinamide
- Where
- 29 sites in Argentina, Australia and 14 more
- Volunteers
- 900 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Latent Tuberculosis
Determining Risk in Latent Tuberculosis
Background: Tuberculosis (TB) is a leading cause of death worldwide. Those who are exposed to the TB bacteria but have not become sick are said to have latent TB.
- Trial name
- NCT01571739
- Where
- South Korea
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Tuberculosis, HIV Coinfection
TB-CAPT EXULTANT - HIV
The overall aim of this study is to assess the potential of an expanded TB testing strategy to increase the number of HIV-positive patients with microbiologically diagnosed TB who are started on treatment in adult wards of…
- Conditions
- Tuberculosis, HIV Coinfection, Diagnoses Disease
- Trial name
- NCT04568967
- Testing
- Concentrated urine with Xpert Ultra, Stool with Xpert Ultra
- Where
- 4 sites in Mozambique, Tanzania
- Volunteers
- 1,172 people
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
Healthy Volunteers
Optimization of Tuberculosis Intradermal Skin Test
The only test available for in vivo diagnosis of tuberculosis is the intradermal injection of tuberculin according to the Mantoux method (also named tuberculosis skin test or PPD skin test).
- Trial name
- TB Dermatest (NCT01611844)
- Testing
- Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative), medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)
- Where
- France
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Acquired Immunodeficiency Syndrome, Tuberculosis
Optimal Time to Initiate Antiretroviral Therapy in HIV & TB Coinfected Adults Being Treated for Tuberculosis
Aim of the study is to determine optimal time to initiate anti-retroviral therapy in HIV/TB co-infected patients who recently started treatment for Tuberculosis by comparing immediate versus deferred initiation of HAART.
- Trial name
- TB-HAART (NCT01315301)
- Testing
- Comparison of different treatment strategies
- Where
- Ethiopia
- Volunteers
- 450 people
- Sponsor
- Karolinska Institutet
Tuberculosis (TB)
Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults
This Phase I study will evaluate the safety and immunogenicity of two doses GSK Biologicals' candidate TB vaccine (692342) according to a 0, 1, 2 months schedule in PPD-negative adults.
- Trial name
- NCT00730795
- Testing
- GSK's candidate Mycobacterium tuberculosis vaccine 692342
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
HIV Infections, Tuberculosis
Appropriate Timing of HAART in Co-infected HIV/TB Patients
To study the optimal timing to initiate antiretroviral therapy in HIV-infected patients who are receiving tuberculosis treatment between at 4 weeks and at 12 weeks after tuberculosis treatment by comparing the composite end point…
- Trial name
- TIME (NCT01014481)
- Testing
- tenofovir, lamivudine, efavirenz
- Where
- Thailand
- Volunteers
- 156 people
- Sponsor
- Bamrasnaradura Infectious Diseases Institute
Tuberculosis, Multidrug-Resistant
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
Multidrug-resistant tuberculosis (MDR-TB) is tuberculosis (TB) that is resistant to at least isoniazid and rifampicin, the two most important anti-TB drugs.
- Trial name
- DRAMATIC (NCT03828201)
- Testing
- Delamanid, Levofloxacin, Bedaquiline
- Where
- 2 sites in Philippines, Vietnam
- Volunteers
- 271 people
- Sponsor
- Boston University
Diagnosis, Tuberculosis
Start Taking Action For TB Diagnosis
Globally, tuberculosis (TB) is one of the main causes of death and the leading cause from a single infectious agent. In 2020, an estimated 9.9 million people developed TB and 1.5 million died.
- Trial name
- START4ALL (NCT05845112)
- Testing
- Class 1, Point of Care (POC) Quantitative C-Reactive Protein (CRP)., Class 2, POC Qualitative/Semiquantitative CRP, Class 3, Urine Lateral Flow Tests
- Where
- 8 sites in Bangladesh, Brazil and 5 more
- Volunteers
- 14,747 people
- Sponsor
- Liverpool School of Tropical Medicine